Nivolumab - CISMeF

Preferred Label : Nivolumab;

NCIt synonyms : NIVO; Anti-PD-1 Human Monoclonal Antibody MDX-1106; Nivolumab Biosimilar CMAB819; Nivolumab Biosimilar ABP 206; Nivolumab Biosimilar BCD-263;

NCIt definition : A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.;

UNII : 31YO63LBSN;

CAS number : 946414-94-4; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 946414-94-4 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Drug name : Opdivo;

Molecule name : ONO-4538; MDX-1106; BMS-936558; CMAB819; ABP 206; BCD-263;

Codes from synonyms : 357;

Details

Origin ID

C68814;

UMLS CUI

C3657270;

Automatic exact mappings (from CISMeF team)
- MDX-1106 [MeSH concept]
- Nivolumab [ICD-11 Extension code]
Currated CISMeF NLP mapping
- Nivolumab [MeSH Descriptor]
- Nivolumab (substance) [SNOMED CT concept]
- nivolumab [MeSH concept]
- nivolumab [International Nonproprietary Name]
See also inter- (CISMeF)
- Product containing nivolumab (medicinal product) [SNOMED CT concept]
- programmed cell death 1 receptor [MeSH Descriptor]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Nivolumab [MeSH Descriptor]
- Nivolumab (substance) [SNOMED CT concept]
- Product containing nivolumab (medicinal product) [SNOMED CT concept]
- nivolumab [MeSH concept]
- nivolumab [ATC Code]
- nivolumab [International Nonproprietary Name]
Validated automatic mappings to BTNT
- nivolumab [ATC Code]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- HL Authorized Value Terminology [NCIt concept]
- HL Protocol Treatment Modifications Table [NCIt concept]
- HL Total Dose Table [NCIt concept]
- HemOnc Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
- NCIt COVID-19 Agent Terminology [NCIt concept]
- NCIt COVID-19 Terminology [NCIt concept]
has_target
- Programmed Cell Death Protein 1 [NCIt concept]
is_component_of_chemotherapy_regimen
- Brentuximab Vedotin/Nivolumab Regimen [NCIt concept]
- CAPOX-Nivolumab Regimen [NCIt concept]
- Cabozantinib/Nivolumab Regimen [NCIt concept]
- Carboplatin/Gemcitabine/Nivolumab Regimen [NCIt concept]
- Carboplatin/Ipilimumab/Nivolumab/Paclitaxel Regimen [NCIt concept]
- Carboplatin/Ipilimumab/Nivolumab/Pemetrexed Regimen [NCIt concept]
- Carboplatin/Nivolumab/Pemetrexed Regimen [NCIt concept]
- Carboplatin/Paclitaxel/Nivolumab Regimen [NCIt concept]
- Cisplatin/Ipilimumab/Nivolumab/Pemetrexed Regimen [NCIt concept]
- Cisplatin/Nivolumab/Pemetrexed Regimen [NCIt concept]
- FOLFOX-Nivolumab Regimen [NCIt concept]
- Ibrutinib/Nivolumab Regimen [NCIt concept]
- Ipilimumab/Nivolumab Followed by Nivolumab Regimen [NCIt concept]
- Ipilimumab/Nivolumab Regimen [NCIt concept]
- N-AVD Regimen [NCIt concept]
- Nivolumab Regimen [NCIt concept]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients